Dems fire off a silly pricing bill; What's wrong with Novartis?
Endpoints assesses the big biopharma stories of the week, with a little added commentary on what they mean for the industry.
The Democrats field few good ideas in a drug pricing bill that is DOA
Any Senate bill that relies on a long list of Democrats for its support doesn’t have much chance of becoming law. But the Dems’ proposed law does help illustrate what Party leaders are thinking these days, and where President Trump may find common ground if the ultra conservative wing of the Republican Party can’t be brought back into the fold.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.